0 Items
Select Page

Crimean Congo Hemorrhagic Fever

Crimean-Congo haemorrhagic fever (CCHF) virus causes a viral haemorrhagic fever transmitted by ticks. CCHF virus responsible for severe outbreaks in humans with a high case fatality ratio of 10-40%. CCHF is endemic in all of Africa, the Balkans, the Middle East and in Asia.

Using our mammalian expression system, we have developed CCHF glycoprotein and nucleoprotein antigens, both of which may be used to detect serological responses to infection.

Crimean Congo Hemorrhagic Fever Background

Crimean Congo Haemorrhagic Fever (CCHF) is a tick-borne infection that is geographically widespread across Africa, Asian, the Middle East and Eastern Europe. It is caused by Crimean Congo haemorrhagic fever virus (CCHFV) – an enveloped, single-stranded RNA virus that belongs to the genus Nairovirus and Bunyaviridae family.

The CCHF virus is primarily maintained in domestic animals and livestock by ticks of the Hyalomma genus (1). However, the virus can be transmitted to humans by CCHFV-infected ticks or through contact with CCHFV-infected animal tissue. Human-to-human transmission can also occur which poses a significant risk to healthcare workers.

In humans, the incubation period of the virus varies with route of exposure. Whilst infected animals remain asymptomatic, CCHFV infection in humans results in a range of clinical symptoms including fever, myalgia, nausea, and headaches before the disease progresses to the haemorrhagic stage (2). According to the World Health Organization (WHO), CCHF can be fatal in 10-40% of cases (3).

Since CCHF was first described in Crimea, in 1944, sporadic outbreaks have occurred globally. In 2015, CCHFV was characterised by the WHO as an emerging virus, likely to cause a severe epidemic and which may present a public health emergency (4). Currently, CCHF viral infection is diagnosed by isolating the virus in early stages of the infection and then by serology, immunofluorescence and molecular techniques. While prophylactic vaccines are in development a safe and effective vaccine has not yet been licensed for use in humans.

References

  1. Spengler, J.R. et al (2016) Seroepidemiological Studies of Crimean-Congo Hemorrhagic Fever Virus in Domestic and Wild Animals. PLoS Negl Trop Dis. 7:10(1):e0004210.
  2. Shayan, S. et al (2015) Crimean-Congo Hemorrhagic Fever. Lab Med. 46:180-9.
  3. World Health Organization – Media centre: Crimean-Congo haemorrhagic fever.
  4. WHO list of top emerging diseases

Crimean Congo Hemorrhagic Fever Antigens

We offer two antigens for CCHFV: glycoprotein N and nucleoprotein, for studies on CCHF biology and serological responses to infection. Both are prepared in our proprietary mammalian cell expression system to ensure correct glycosylation and native folding.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Clostridium difficile Toxins: The Nuts and Bolts

In this blog, we describe the mechanisms of action of the Clostridium difficile A and B toxins, and discuss their use in research and medicine. The Native Antigen Company provides biologically active C. diff toxins, as well as inactivated toxoids for a range of...

Where Are We At with CMV Vaccine Development?

In this blog, we discuss the need for a CMV vaccine, the current vaccine strategies that are in development, and introduce our range of CMV antigens and antibodies.Cytomegalovirus The human Cytomegalovirus (CMV) is an enveloped, icosahedral 150-200nm pleomorphic...

Paper Synopsis: Measles Induces Immune Amnesia

In the midst of widespread concern about growing anti-vaccination sentiments, worldwide, a study published this month suggests that Measles virus infection can also ablate acquired immunity to other diseases. In this blog, we introduce the concept of immune amnesia,...

Achieving Diagnostic Specificity with Dengue Envelope Domain III

In this blog, we discuss the structure and function of Flavivirus Envelope protein, its ability to elicit a broad range of antibody responses, and present our new range of Dengue virus Envelope DIII proteins for diagnostic and vaccine development.Envelope Protein: A...

Coronaviruses: The Next Disease X?

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

8 + 14 =

Live Customer Feedback

Join our mailing list

* indicates required